Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 382

Results For "EU"

5723 News Found

Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData
News | December 07, 2022

Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData

The use of procalcitonin testing for sepsis management is highest in the US


Concord Biotech gets SEBI nod for IPO
News | December 07, 2022

Concord Biotech gets SEBI nod for IPO

The IPO is a complete OFS by existing shareholder Helix Investment Holdings


Healthium divests its UK based continence care organization Clinisupplies
News | December 07, 2022

Healthium divests its UK based continence care organization Clinisupplies

Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio


Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations
News | December 07, 2022

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations

GMP-compliant documentation of all manufacturing steps for cell and gene therapies


BASF Pharma Solutions excipient accepted into FDA Pilot Program
Drug Approval | December 06, 2022

BASF Pharma Solutions excipient accepted into FDA Pilot Program

Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients


Biocon Biologics elevates Shreehas Tambe as MD & CEO
People | December 06, 2022

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.


JB Pharma reduces price of Azmarda by 50%
News | December 06, 2022

JB Pharma reduces price of Azmarda by 50%

Move to increase affordability and accessibility for heart failure patients across the country


Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
News | December 05, 2022

Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints